Trials / Completed
CompletedNCT06184841
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Hepatic Arterial Infusion Chemotherapy Combined Sintilimab for Predominant Liver Metastasis From Esophageal Squamous Cell Carcinoma- A Pilot Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic therapy. However, for those with predominant liver disease or failure of system therapy, local liver management becomes an option. This prospective single center study aimed to evaluate the efficacy and adverse events of hepatic arterial infusion chemotherapy (HAIC) using percutaneous catheter placement techniques for liver metastases from esophagus squamous (ESC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HAIC combined with intravenous PD-1 | Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks. |
Timeline
- Start date
- 2020-06-18
- Primary completion
- 2023-10-18
- Completion
- 2023-12-01
- First posted
- 2023-12-28
- Last updated
- 2023-12-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06184841. Inclusion in this directory is not an endorsement.